Group 1 - The company, Guichuang Tongqiao, repurchased 50,000 shares at an average price of HKD 23.68 per share, totaling approximately HKD 1.1842 million, with a cumulative repurchase of 4.1145 million shares this year, representing 1.29% of the total share capital [1] - The recent stock repurchase activity may indicate management's confidence in the company's future development and belief that the current stock price is undervalued [1] - Stock buybacks are often viewed as a positive signal, potentially reducing the number of shares in circulation, thereby enhancing earnings per share and stock price [1] Group 2 - Guichuang Tongqiao is an innovative medical device company listed on the Hong Kong Stock Exchange, focusing on the research, production, and sales of peripheral vascular interventional medical devices [2] - The company aims to provide high-quality and innovative medical solutions, with products including balloon dilation catheters and stents, capturing a certain market share in the growing medical device industry [2] - The business development of Guichuang Tongqiao is closely linked to the increasing global demand for medical services, particularly in light of the rising attention to vascular diseases, indicating a broad market prospect for its products [2]

智通财经APP讯，归创通桥(02190)发布公告，于2025年8月25日，该公司斥资118.42万港元回购5万股。 ...

格隆汇8月25日丨归创通桥(02190.HK)公告，8月25日耗资118万港元回购5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Insights - The neurointervention sector has undergone significant changes since the implementation of centralized procurement in 2021, leading to increased investment interest in domestic medical devices with low localization rates [1][2] - Domestic companies like Guichuang Tongqiao have shown strong performance in centralized procurement, with revenue growth of 31.7% and net profit growth of 76% in the first half of the year [1][2] - The market is characterized by a high proportion of imported brands, with 80% in the neurovascular intervention market and 85% in the peripheral vascular intervention market [1][2] Group 1: Market Dynamics - Centralized procurement has become a critical turning point for the pharmaceutical industry, with some leading companies losing market share while others capitalize on procurement opportunities [2][3] - Guichuang Tongqiao's core business in neurovascular and peripheral vascular intervention products saw sales growth of 25.0% and 46.2% respectively [2][3] - The average price drop for products in centralized procurement ranges from 10% to 25%, with specific products like spring coils seeing a price reduction from 12,000 yuan to a minimum of 3,277 yuan [2][3] Group 2: Future Trends - The trend towards domestic production and the strengthening of leading domestic companies is expected to continue, with improved gross and net profit margins anticipated for companies [3][5] - The National Medical Insurance Administration is optimizing procurement rules, which may lead to more reasonable pricing strategies among companies [3][5] - The volume of neurointervention surgeries is expected to grow, supported by the implementation of DRG 2.0 pricing regulations and the anticipated increase in usage of drug balloons following the upcoming sixth batch of national procurement [4][5] Group 3: Company Performance - Guichuang Tongqiao has set a net profit guidance of 150 million yuan for 2025, having already achieved 120 million yuan in the first half of the year [5] - The company remains confident in exceeding its previous annual profit expectations, despite anticipating higher expenses in the second half of the year [5]

Core Viewpoint - The company reported strong financial performance in H1 2025, with significant growth in both revenue and net profit, indicating a robust business trajectory and effective commercialization strategies [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 482 million yuan, representing a year-on-year increase of 31.7% - Net profit surged to 121 million yuan, reflecting a growth of 76.0% - The gross margin remained stable at 71.2%, with a slight decrease of 0.1 percentage points, while the net profit margin reached 25.1% [1]. Business Segments - **Neurointervention**: Revenue from neurointervention reached 304 million yuan, up 25.0%, driven by strong sales of established products and rapid adoption of newer products in hospitals [1]. - **Peripheral Intervention**: The peripheral vascular intervention segment generated approximately 176 million yuan, marking a 46.2% increase, with significant contributions from both mature and newly commercialized products [1]. Product Development and Innovation - The company has a portfolio of 73 products or candidates, with 50 already commercialized in China - New products expected to be approved in H2 2025 include large-bore peripheral thrombectomy catheters and auxiliary embolization stents [2]. - The self-expanding aneurysm embolization device is in development and is anticipated to enter the market by 2027 [2]. Market Expansion - The company has established a strong sales network covering over 3,000 hospitals in China, effectively translating R&D capabilities into commercial success - The company is leveraging centralized procurement to accelerate product adoption in hospitals [2]. - The overseas market presents significant growth potential, with current domestic market shares in neurointervention and peripheral intervention at only 15-20% and 12-15% of the global market, respectively [2]. - In H1 2025, overseas revenue reached 16 million yuan, a 36.9% increase, with 22 products commercialized in 27 countries [2]. Investment Outlook - Based on H1 2025 performance, the company is projected to achieve net profits of 195 million yuan, 279 million yuan, and 378 million yuan for 2025-2027, representing year-on-year growth rates of 95.0%, 42.7%, and 35.7% respectively - The expected earnings per share (EPS) for the same period are 0.59 yuan, 0.84 yuan, and 1.15 yuan, with corresponding price-to-earnings (PE) ratios of 36, 25, and 19 [3].

在归创通桥业绩交流会上，公司管理层表示，集采政策持续优化，降价呈现温和趋势。"公司从2020年 12月开始有产品参与集采，到目前为止，取得的业绩还是不错，在应对集采方面也积累了一些经验。中 国的神经血管介入市场，进口品牌占比80%；外周血管介入市场，进口品牌占比也高达85%，预计未来 国产替代趋势不会改变，公司在存量市场中寻找增量。" 值得注意的是，为推进以按病种付费为主的多元复合式医保支付方式改革，国家医保局近日已正式印发 《医疗保障按病种付费管理暂行办法》。医保按病种付费是指通过对疾病诊疗进行分组或折算分值，实 行医保对医疗机构的"打包付费"。该政策对介入手术影响多大？ 在去年实现首次盈利后，归创通桥（02190.HK）今年上半年业绩继续维持增长。 根据归创通桥近日发布的半年报显示，今年上半年，公司实现收入4.82亿元，同比增长31.7%；净利润 1.21亿元，同比增长76%。 作为介入耗材厂商，归创通桥的收入主要来源于神经血管介入、外周血管介入这两大类产品。得益于中 标集采后带来的销量增加，公司介入产品在医院的渗透率持续在提高。2025年上半年，神经血管介入产 品的销售收入同比增长25.0%；外周血管介 ...

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 30.4 HKD [2][8]. Core Insights - The company reported a significant revenue increase of 31.7% in H1 2025, achieving 482 million CNY, and a net profit growth of 76.0%, reaching 121 million CNY [2][8]. - The company is experiencing strong growth in both its neurointervention and peripheral intervention segments, with revenues of 304 million CNY (+25.0%) and 176 million CNY (+46.2%) respectively in H1 2025 [8]. - The company has a robust product pipeline with 73 products or candidates, of which 50 are already commercialized in China, and several new products are expected to be approved in the near future [8]. - The overseas market is identified as a new growth driver, with H1 2025 overseas revenue reaching 16 million CNY (+36.9%), and the company has 22 products commercialized in 27 countries [8]. Financial Summary - The company is projected to achieve total revenue of 1,044 million CNY in 2025, with a year-on-year growth rate of 33.5% [4]. - The net profit for 2025 is estimated at 195 million CNY, reflecting a substantial growth of 95.0% compared to the previous year [4]. - The earnings per share (EPS) are forecasted to be 0.59 CNY for 2025, with a corresponding price-to-earnings (P/E) ratio of 36.4 [4][8].

Core Viewpoint - The company is expected to see significant growth in adjusted profits due to the expansion of its neuro/peripheral products and effective cost management, leading to an upward revision of profit forecasts for 2025 and 2026 [1][2] Financial Performance - In 1H25, the company reported revenue of 482 million, a year-on-year increase of 31.7%, and an adjusted net profit of 131 million, up 68.1% year-on-year, exceeding expectations due to accelerated domestic substitution in its neuro/peripheral business lines and effective cost control [2] Business Growth Drivers - The neuro/peripheral business saw revenue growth of 25% and 46% respectively in 1H25, driven by increased hospital penetration of existing products and strong sales of new products such as mesh stents and vascular sutures, indicating a solid market position and potential for further growth [3] Profitability and Management Confidence - The adjusted net profit margin reached 27.3% in 1H25, with the company initiating cash dividends for the first time in 2024 at a payout ratio of 32%, alongside ongoing share buybacks and a new equity incentive plan, reflecting management's confidence in future growth [4] International Expansion Potential - The global market for peripheral and neuro intervention is projected to reach 10 billion and 7 billion respectively by 2024, with China currently accounting for only 12-15% and 15-20% of these markets, indicating significant international growth opportunities [5]

| 股票名称 | 回购数 | 回购额 | 年累计回购数量(股) | 年累计回购数量/总 | | --- | --- | --- | --- | --- | | | | | | 股本 | | 腾讯控股(00700) | 92.80 万 | 5.51 亿 | 4119.50 万 | 0.448% | | 中国宏桥(01378) | 146.95 万 | 3516.03 万 | 5411.10 万 | 0.580% | | 创科实业(00669) | 25.00 万 | 2508.49 万 | 100.00 万 | 0.055% | | 恒生银行(00011) | 20.00 万 | 2249.35 万 | 300.00 万 | 0.159% | | 北森控股(09669) | 45.00 万 | 356.53 万 | 734.50 万 | 1.046% | | 元征科技(02488) | 17.40 万 | 196.76 万 | 236.45 万 | 1.464% | | 康宁医院(02120) | 12.09 万 | 127.75 万 | 46.31 万 | 0.640% | | 归创通桥-B(02190) | ...